224 related articles for article (PubMed ID: 31492560)
1. Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Yu Y; Suryo Rahmanto Y; Shen YA; Ardighieri L; Davidson B; Gaillard S; Ayhan A; Shi X; Xuan J; Wang TL; Shih IM
EBioMedicine; 2019 Sep; 47():184-194. PubMed ID: 31492560
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway.
Yu Y; Suryo Rahmanto Y; Lee MH; Wu PH; Phillip JM; Huang CH; Vitolo MI; Gaillard S; Martin SS; Wirtz D; Shih IM; Wang TL
Oncogene; 2018 Jul; 37(28):3778-3789. PubMed ID: 29643476
[TBL] [Abstract][Full Text] [Related]
3. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
Yuan T; Wang Y; Zhao ZJ; Gu H
J Biol Chem; 2010 May; 285(20):14861-14870. PubMed ID: 20335174
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
Parashar D; Nair B; Geethadevi A; George J; Nair A; Tsaih SW; Kadamberi IP; Gopinadhan Nair GK; Lu Y; Ramchandran R; Uyar DS; Rader JS; Ram PT; Mills GB; Pradeep S; Chaluvally-Raghavan P
Cancer Res; 2020 Dec; 80(24):5554-5568. PubMed ID: 33087324
[TBL] [Abstract][Full Text] [Related]
5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
6. Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells.
Ruschel A; Ullrich A
Cell Signal; 2004 Nov; 16(11):1249-61. PubMed ID: 15337524
[TBL] [Abstract][Full Text] [Related]
7. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
[TBL] [Abstract][Full Text] [Related]
8. STING-Mediated Interferon Induction by Herpes Simplex Virus 1 Requires the Protein Tyrosine Kinase Syk.
Wang C; Sharma N; Veleeparambil M; Kessler PM; Willard B; Sen GC
mBio; 2021 Dec; 12(6):e0322821. PubMed ID: 34933455
[TBL] [Abstract][Full Text] [Related]
9. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract][Full Text] [Related]
10. The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2.
Zeineldin R; Ning Y; Hudson LG
J Histochem Cytochem; 2010 Jun; 58(6):529-41. PubMed ID: 20159766
[TBL] [Abstract][Full Text] [Related]
11. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
12. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
13. Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH.
Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE
Cell Signal; 2012 Nov; 24(11):1981-8. PubMed ID: 22800866
[TBL] [Abstract][Full Text] [Related]
14. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
15. The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
17. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
18. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.
Sereni MI; Baldelli E; Gambara G; Deng J; Zanotti L; Bandiera E; Bignotti E; Ragnoli M; Tognon G; Ravaggi A; Meani F; Memo M; Angioli R; Liotta LA; Pecorelli SL; Petricoin E; Pierobon M
Proteomics; 2015 Jan; 15(2-3):365-73. PubMed ID: 25311472
[TBL] [Abstract][Full Text] [Related]
20. Spleen Tyrosine Kinase Mediates EGFR Signaling to Regulate Keratinocyte Terminal Differentiation.
Wu NL; Huang DY; Wang LF; Kannagi R; Fan YC; Lin WW
J Invest Dermatol; 2016 Jan; 136(1):192-201. PubMed ID: 26763439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]